🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Stephen Welch

Western University

ORCID: 0000-0003-1455-4664

Also affiliated with Cancer Care Ontario, London Health Sciences Centre

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 4 papers. Top paper: “Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma”.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Annals of Oncology(2024)10.1016/j.annonc.2024.02.005
N/A
0.868DataRank · unranked
326 citations

S.L. Chan, R.K. Kelley, G. Lau, M. Kudo, W. Sukeepaisarnjaroen +198 more

Patient self-reporting of tolerability using PRO-CTCAE: A randomized double-blind placebo controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in women with platinum resistant epithelial ovarian cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5541
N/A
0DataRank · unranked
3 citations

Sandra A. Mitchell, Tyler Pittman, Lisa Wang, Valerie Bowering, Nisan Kavak +9 more

1223TiP A randomized phase III study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG-3098/ENGOT-EN24

Annals of Oncology(2025)10.1016/j.annonc.2025.08.1858
N/A
0DataRank · unranked
1 citations

P. Follana, Melissa A. Geller, Elena Ioana Braicu, S. Ghamande, Ignacio A. Romero +13 more

Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.

Journal of Clinical Oncology(2018)10.1200/jco.2018.36.15_suppl.5576
N/A
0DataRank · unranked
0 citations

Liz-Anne Lewsley, Gennaro Daniele, Adrian David Cook, Nozomu Yanaihara, Anna Tinker +14 more